A Phase 1 Study of Ruxolitinib, Lenalidomide and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.

CONCLUSIONS: This study provides the basis for studying the addition of JAK inhibitors to improve the efficacy of immunomodulatory agents with steroids for treating myeloma patients but perhaps can also be expanded for treating other cancer patients that are refractory to this class of drugs.
PMID: 31937615 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 13, 2020 Category: Cancer & Oncology Authors: Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, Ghermezi M, Eades BM, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, Vescio R Tags: Clin Cancer Res Source Type: research